Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRAW: Aflibercept PK in Vitrectomized vs Non-vitrectomized Eyes
NCT02204683Phase 1Completed
- Sponsor
- University of Nebraska
- Start
- Sep 2014
- Primary completion
- Dec 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of aflibercept in exudative macular degeneration (2 arms), sponsored by University of Nebraska. Primary endpoint: Pharmacokinetic (PK) aflibercept aqueous at 28 days. Started Sep 2014; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02204683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204683.